is exendin 4 in tirzepatide Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction | Cardiovascular Diabetology Tirzepatide modulates the regulation of

As one obesity medicine specialist explained, "the increased risk of thyroid cancers is specifically in those with a personal or family history of multiple endocrine neoplasia 2 (MEN2) syndrome or medullary thyroid carcinoma [MTC]." Reassuringly, randomized trials failed to detect any increase in calcitonin levels and did not confirm the risk of pancreatitis, whereas a significant increase in cholelithiasis was highlighted

Kouli A, Torsney KM, Kuan W-L

have thyroid disease

It links this to duration in its evidence section too, saying short courses of two weeks or less rarely require a GLP-1 change while prolonged therapy beyond four weeks frequently does

Some studies suggest that patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks